AVTX · XBRL financial data
Avalo Therapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AVTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 6,699 | 5,398 | 18,051 | 1,924 | 441 | 59 |
| Cost of goods and services sold | 300 | 1,491 | 3,434 | 1,284 | — | — |
| Selling, general and administrative | — | — | 20,711 | 10,300 | — | — |
| General and administrative | 17,417 | 21,832 | 20,711 | 10,300 | 17,241 | 22,900 |
| Operating income (loss) | (72,843) | (82,134) | (37,440) | (27,351) | (68,512) | (72,925) |
| Other income (expense) | 410 | (20) | (20) | (42) | (5) | — |
| Income tax expense (benefit) | (2,793) | (196) | 28 | 14 | 114 | 165 |
| Net income (loss) | (63,500) | (84,376) | (41,658) | (31,544) | (35,129) | (78,259) |
| Earnings per share, basic‡ USD per share | — | — | (1,054.76) | (114.00) | (7.94) | (5.84) |
| Earnings per share, diluted‡ USD per share | — | — | (1,054.76) | (114.00) | (20.91) | (5.84) |
| Weighted average shares, basic‡ thousands of shares | — | — | 40 | 278 | 4,426 | 13,405 |
| Weighted average shares, diluted‡ thousands of shares | — | — | 40 | 278 | 7,496 | 13,405 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-238.0952380952381 stock split (December 2023); filings made before it reported them unadjusted.
- † Share count changed about 19x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AVTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18,919 | 54,585 | 13,172 | 7,415 | 134,546 | 15,858 |
| Short-term investments | — | — | — | — | 0 | 82,478 |
| Accounts receivable | — | — | 0 | — | — | — |
| Inventory | 3 | 38 | 20 | 0 | — | — |
| Prepaid and other current assets | 2,660 | 2,372 | 1,290 | 843 | 3,714 | 6,913 |
| Total current assets | 26,005 | 61,845 | 16,416 | 8,395 | 138,890 | 105,286 |
| Right-of-use asset | 917 | 2,001 | 1,750 | 1,329 | 741 | 336 |
| Goodwill | 14,409 | 14,409 | 14,409 | 10,502 | 10,502 | 10,502 |
| Total assets | 43,755 | 80,214 | 33,367 | 20,993 | 150,732 | 116,458 |
| Accounts payable | 2,574 | 3,369 | 2,882 | 446 | 283 | 137 |
| Total current liabilities | 15,225 | 19,888 | 22,114 | 4,618 | 6,960 | 12,940 |
| Lease liability, non-current | 1,038 | 2,018 | 1,711 | 1,366 | 350 | 35 |
| Total liabilities | 19,194 | 57,132 | 44,282 | 13,689 | 17,700 | 33,409 |
| Accumulated deficit | (177,790) | (262,166) | (303,824) | (335,134) | (370,263) | (448,522) |
| Total stockholders' equity | 24,562 | 23,082 | (10,915) | 7,304 | 133,032 | 83,049 |
| Total liabilities and equity | 43,755 | 80,214 | 33,367 | 20,993 | 150,732 | 116,458 |
| Common shares outstanding (cover page)‡ thousands of shares | 31 | 39 | 55 | 1,034 | 10,672 | 22,788 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-238.0952380952381 stock split (December 2023); filings made before it reported them unadjusted.
- † Share count changed about 19x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AVTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (63,500) | (84,376) | (41,658) | (31,544) | (35,129) | (78,259) |
| Stock-based compensation | 6,786 | 8,172 | 7,554 | 3,477 | 5,852 | 13,621 |
| Depreciation and amortization | 1,843 | 1,657 | 166 | 158 | 169 | 344 |
| Net cash from operating activities | (40,540) | (70,892) | (26,751) | (30,680) | (49,056) | (51,458) |
| Purchases of property and equipment | 63 | 113 | 95 | — | — | — |
| Net cash from investing activities | 11,132 | (113) | (95) | (133) | 356 | (81,720) |
| Proceeds from issuing common stock | 35,428 | 29,046 | 0 | 46,200 | 0 | 14,762 |
| Repayments of long-term debt | 0 | — | — | — | — | — |
| Net cash from financing activities | 44,785 | 106,762 | (14,699) | 25,042 | 175,849 | 14,587 |
| Net change in cash | 15,377 | 35,757 | (41,545) | (5,771) | 127,149 | (118,591) |
- † Share count changed about 19x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Avalo Therapeutics | 85,382 | not reported | (19,988)* | 53.6M | 20.0 quarters | 10-QJun 30, 2026 |
| Cue Biopharma | 17,392 | 7,877 | (29,004)* | 7.3M | 0.6 quarters | 10-QJun 30, 2026 |
| Fitlife Brands | 1,089 | not reported | 3,635* | 9.4M | — | 10-QJun 30, 2026 |
| Immucell | 8,860 | 7,186 | 3,019* | 9.1M | — | 10-QJun 30, 2026 |
| iBio | 56,395 | 0* | (6,228)* | 64.3M | 14.1 quarters | 10-KJun 30, 2026 |
| Sutro Biopharma | 54,335 | 9,839 | (38,290)* | 16.6M | 4.3 quarters | 10-QJun 30, 2026 |
| PDS Biotechnology | 5,596 | not reported | (2,793)* | 56.0M | 2.0 quarters | 10-QJun 30, 2026 |
| Precision Biosciences | 81,698 | 0 | (15,132)* | 27.9M | 6.1 quarters | 10-QSep 30, 2026 |
| Medicinova | 25,416 | 458 | (1,920)* | 49.2M | 13.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.